Why Magic Mushrooms Are Emerging As Major Part Of Public Discourse: How Are They Commercialized?
(Part four of a four-part series)
Is Psilocybin Therapy A Potential Treatment For Fibromyalgia & Binge Eating Disorder?
Clinical-stage developer of psychedelic compounds Tryp Therapeutics Inc. (OTCQB: TRYPF) filed two provisional patent applications - one for psilocybin therapy for fibromyalgia and another expanding psilocybin-based TRP-8803 development’s IP.
Psychedelics Developer & Mass-Scale Manufacturer Will Deliver Novel Magic Mushroom Products
Life sciences biotech company Core One Labs Inc. (OTCQB: CLABF) signed a Letter of Intent with GMP-certified manufacturer Medelys Laboratories International Inc. for the manufacturing of its proprietary psychedelic active pharmaceutical ingredient (API) products.
Psyched: Magic Mushrooms Vs. Psychotherapy, Psilocybin For Frontline Health Workers & Protecting Peyote
As news about psychedelics research and successful applications sweeps across the country and abroad, Psyched is back to wrap up the exciting movement of this rapidly evolving sector.
Magic Mushrooms For Anorexia? Clinical Study Receives FDA Approval For Phase 2 Trial
Origin Therapeutics Holdings Inc. (CSE: ORIG), a psychedelics industry-focused investment issuer, announced that one of its portfolio companies, Xpira Pharmaceuticals, has obtained approval from the FDA for its first Investigational New Drug (IND) application for a Phase 2a psilocybin therapy clinical study for anorexia nervosa.
Clinical Study On DMT Inhaled Product For Treatment-Resistant Depression Completes Dosing Stage
Biomind Labs Inc. (OTC: BMNDF), a life sciences company developing medicinal next-generation psychedelics, completed the dose administration of 30 healthy subjects within its Phase 2 clinical trial of DMT-based proprietary drug BMND01 for the Treatment-Resistant Depression (TDR) disorder.
Ketamine Therapy Growing In US And Canada With This Novel Montreal Clinic
Legal ketamine-assisted therapy for people with diagnosed mental health conditions continues to expand throughout the U.S. and Canada.
Two Psychedelics Companies Will Study Effects Of Natural Psilocybin And MDMA In Healthy Volunteers
Health Canada receives applications concerning clinical trials on a regular basis. This time, the licensed producer of natural EU-GMP psilocybin and MDMA Optimi Health Corp.
Why Magic Mushrooms Are Emerging As Major Part Of Public Discourse: What Science Is Saying
(Part three of a four-part series)
Despite ongoing legal setbacks, psychedelics research has reemerged and it is proving that psilocybin reduces brain connections within the usual networks while amplifying links between less connected areas.
Clinical Research Comparing Effects Of Novel MDMA Matches In Healthy Patients Begins In Switzerland
The clinical trial investigating the effects of MDMA analogs in healthy volunteers led by PI Prof. Dr. Matthias Liechti and supported by psychedelics biotech company Mind Medicine Inc. (NASDAQ: MNMD) has begun patient dosing.